New research reveals affluent Brits are spending nearly £10,000 a year on longevity – but experts urge caution

woman in black sports bra and black pants running on water during sunset

From luxury longevity retreats to wearable glucose trackers, the pursuit of living healthier for longer was once largely associated with the ultra-wealthy. 

But experts say the trend is increasingly being adopted by affluent professionals – and could become more mainstream as more people look for ways to extend not just their lifespan, but the number of years they spend in good health. 

New research from AXA Global Healthcare found wealthy UK professionals are spending an average of nearly £10,000 a year on longevity-focused healthcare, with some investing more than £50,000 annually. 

The spending ranges from personal trainers and stress management through to advanced diagnostics and more specialist medical treatments, including experimental use. 

While some treatments remain firmly in the luxury bracket, other elements of the longevity boom – including wearable health trackers, personalised nutrition programmes and more advanced preventative health screening – are increasingly being packaged for and adopted by a wider audience. 

Dr Mayoni Gooneratne, a longevity expert and Functional Medicine Director at PHC Clinics, said more people now see ageing as something they can actively influence rather than simply accept. 

She explained: “People are more aware that lifestyle and cardiometabolic risk explain a large share of premature ageing and chronic disease, and that these are modifiable. So longevity now feels more controllable than it did a decade ago.” 

Dr Gooneratne said growing access to wearable technology and preventative healthcare has helped fuel the shift, giving people more real-time information about their health. 

“The consumerisation of health tech gives people more real-time feedback, which is motivating but can also create the sense that every metric can and should be optimised,” she said. 

The AXA Global Healthcare study found fitness and personal training was the most common area of longevity spending, with 53% of respondents investing in it over the past year. 

Mental health, sleep optimisation and stress management followed at 36%, while nearly three in 10 (29%) spent money on personalised nutrition and metabolic health programmes. 

Meanwhile, 18% reported investing in continuous health monitoring such as wearable devices and glucose trackers, while smaller groups also paid for advanced diagnostic screening (15%), concierge-led medical care (13%) and longevity-directed medications and supplements, including experimental use (16%). 

Nearly three-quarters (74%) of respondents said they plan to increase their spending on longevity-focused healthcare over the next three years. 

The research also found that almost half (47%) of respondents had already travelled abroad for longevity treatments, while a further 37% said they would consider doing so. 

Dr Gooneratne said some people are travelling overseas in search of newer or more specialist treatments. 

She explained: “Patients who travel specifically for treatments not yet approved at home are usually driven by a combination of hope, impatience and a desire to be ahead of the curve.” 

However, the doctor warned that expensive “biohacking” treatments and anti-ageing interventions are not a shortcut to a longer life. 

More than half (53%) of respondents said they expect longevity interventions to add at least six extra healthy years to their lives. 

Dr Gooneratne said that while those expectations may sound ambitious, the strongest evidence still points towards relatively simple long-term lifestyle habits. 

She said: “Large-scale studies consistently show that combining core lifestyle changes – like staying active, maintaining a healthy weight, eating well and not smoking – can add around six to seven years of life, much of it in better health.” 

But she warned the science behind some emerging treatments is still developing. 

“There’s understandable excitement around drugs like metformin and rapamycin, but the evidence in humans is still at an early stage,” she said. 

“We’re seeing promising signals and strong results in animal studies, but robust data on extending lifespan in people just isn’t there yet.” 

Dr Gooneratne added that while luxury clinics and expensive testing often dominate the conversation around longevity, many of the most effective changes remain accessible to most people. 

“The underlying intuition – that proactive, data-driven prevention can add years of good life – is right,” she said. 

“But the marketplace sometimes over-credits the newest or most expensive intervention rather than the unglamorous basics that move most of the dial.”